Tennessee Senate Bill SB1848

Tennessee 2025-2026 Regular Session

• Introduced: 1/21/26
• Chaptered: 4/24/26
• Passed: 4/24/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to the use of buprenorphine products.

Impact

The changes proposed by SB 1848 emphasize the importance of direct administration of buprenorphine by licensed healthcare providers under strict conditions. These amendments are intended to enhance patient safety by ensuring that patients are closely monitored during treatment, while also restricting how the medication can be dispensed. As a result, the bill is expected to strengthen the oversight of buprenorphine use in the state, supporting efforts to combat substance use disorders while minimizing potential risks associated with misuse or diversion of the medication.

Summary

Senate Bill 1848 aims to amend Tennessee Code Annotated, Title 53, Chapter 11, specifically concerning the regulation of buprenorphine products, which are used for the treatment of substance use disorder. The bill clarifies the conditions under which buprenorphine can be administered, focusing on preventing misuse while ensuring that patients receive necessary treatment. The legislation is oriented towards improving healthcare provider guidelines and maintaining patient care standards in the context of opioid treatment policies.

Sentiment

The sentiment surrounding SB 1848 appears largely supportive among healthcare professionals and lawmakers concerned with public health and safety. Proponents argue that tightened regulations on buprenorphine usage are critical for ensuring the welfare of patients undergoing treatment for substance use disorders. However, there seems to be some concern among advocates for patients’ rights regarding access to treatment and whether these regulations might inadvertently create barriers for those in need of immediate care.

Contention

Notable points of contention include the balance between ensuring patient safety and providing access to necessary treatment for substance use disorders. Critics of stringent regulations may express worries that overly restrictive policies could lead to accessibility issues for vulnerable populations, particularly for pregnant women or nursing mothers who may require buprenorphine. The debates surrounding SB 1848 highlight the ongoing struggle within the healthcare system to effectively address opioid dependency while promoting safe treatment protocols.